loading...| Preferred Name |
Dexrazoxane |
|
| Synonyms |
|
|
| Definitions |
A bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1333 |
|
| Accepted_Therapeutic_Use_For |
Chemotherapy-induced cardiomyopathy |
|
| ALT_DEFINITION |
The active ingredient in a drug used to treat severe side effects caused by certain anticancer drugs. Under the brand name Totect it is used to treat the toxic effects of an anticancer drug that leaks from a vein into surrounding tissue and causes tissue damage. Under the brand name Zinecard it is used to reduce heart damage in women given doxorubicin for breast cancer that has spread. Dexrazoxane is also being studied in the treatment of cancer. It is a type of cardioprotective agent, a type of chemoprotective agent, and a type of topoisomerase inhibitor. |
|
| CAS_Registry |
24584-09-6 |
|
| CHEBI_ID |
CHEBI:50223 |
|
| Chemical_Formula |
C11H16N4O4 |
|
| code |
C1333 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173243 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C186329 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C174019 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C186341 |
|
| Contributing_Source |
CTRP FDA PCDC |
|
| DEFINITION |
A bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition. |
|
| Display_Name |
Dexrazoxane |
|
| FDA_UNII_Code |
048L81261F |
|
| FULL_SYN |
2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-,(S)-(9CI) (+)-(S)-4,4'-(1-Methyl-1,2-ethanediyl)di(2,6-piperazinedione) DEXRAZOXANE Razoxane (+)-form 2,6-Piperazinedione, 4, 4'-(1-methyl-1,2-ethanediyl)bis-, (S)- (9CI) 2,6-Piperazinedione, 4,4'propylenedi-,(P)-(8CI) Dexrazoxane dexrazoxane Soluble ICRF (L-isomer) 2, 6-Piperazinedione, 4,4'-propylenedi-, (P)- (8CI) ADR-529 ICRF-187 |
|
| Has_Salt_Form | ||
| Is_PCDC_AML_Permissible_Value_For_Variable | ||
| Is_Value_For_GDC_Property | ||
| label |
Dexrazoxane |
|
| Legacy Concept Name |
Dexrazoxane |
|
| Maps_To |
Dexrazoxane |
|
| NSC Number |
169780 |
|
| Preferred_Name |
Dexrazoxane |
|
| prefixIRI |
Thesaurus:C1333 |
|
| prefLabel |
Dexrazoxane |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C0086444 |
|
| 文本定义 |
A bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition. |
|
| subClassOf |